Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis
Sponsor: Entasis Therapeutics
A PHASE2 clinical study on Acute Pyelonephritis and Complicated Urinary Tract Infection, this trial is completed. The trial is conducted by Entasis Therapeutics and has accumulated 11 data snapshots since 2018. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jul 2019 — Feb 2020 [monthly]
Completed PHASE2
-
Feb 2019 — Jul 2019 [monthly]
Completed PHASE2
-
Jul 2018 — Feb 2019 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Jan 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Entasis Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .